WHO calls to action on blindness

Article

The global initiative Vision2020: Right to Sight has received a major boost following the endorsement of the WHO Action Plan for the Prevention of Avoidable Blindness and Visual Impairment by the 62nd World Health Assembly, the WHO governing body.

The global initiative Vision2020: Right to Sight has received a major boost following the endorsement of the WHO Action Plan for the Prevention of Avoidable Blindness and Visual Impairment by the 62nd World Health Assembly, the WHO governing body.

WHO team leader for Prevention of Blindness & Deafness, Dr. Ivo Kocur said: “Adoption of the Action Plan by the WHA is a major accomplishment and will provide additional unprecedented support to VISION 2020 and our joint efforts to improve eye health internationally.”>

The plan aims to expand the efforts made by member states, WHO and international partners in Vision 2020 to help prevent blindness and visual impairment by the development of comprehensive eye health programmes at national & sub-national levels. It sets out current experience, draws on the recognised achievements and deals with gaps in implementing activities over the past decades.

OTEurope is fully supportive of the work of Vision2020 and is looking forward to highlighting more of its work over the coming months.

The current Action Plan can be downloaded from the WHO website here and full coverage of the 62nd World Health Assembly is available online

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.